Cardio-Oncology and Breast Cancer Therapies

被引:0
作者
Singh, Rohit [1 ,2 ]
Patel, Krina [3 ]
Xu, Haze [1 ,2 ]
Adeniyi, Aderonke [4 ]
Upshaw, Jenica N. [3 ]
Van Buren, Peter [5 ]
Kaufman, Peter A. [1 ,2 ]
Dittus, Kim [6 ]
Landry, Kara K. [1 ,2 ]
机构
[1] Univ Vermont, Larner Coll Med, Dept Med, Div Hematol Oncol, Burlington, VT 05405 USA
[2] Univ Vermont, Canc Ctr, Burlington, VT 05405 USA
[3] Tufts Med Ctr, Dept Med, Div Cardiol, Boston, MA USA
[4] Wake Forest Baptist Med Ctr, Dept Internal Med, Div Cardiol, Winston Salem, NC USA
[5] Univ Vermont, Larner Coll Med, Dept Med, Div Cardiol, Burlington, VT USA
[6] Univ Wisconsin, Dept Med, Div Hematol Oncol, Madison, WI USA
关键词
Breast cancer; Cardio-oncology; Cardiotoxicity; IMMUNE CHECKPOINT INHIBITORS; PLUS ENDOCRINE THERAPY; ANTHRACYCLINE CARDIOTOXICITY; FOLLOW-UP; ADJUVANT CHEMOTHERAPY; TRASTUZUMAB EMTANSINE; OPEN-LABEL; PREDICTIVE MODEL; HEART-FAILURE; DOXORUBICIN;
D O I
10.1007/s11864-025-01311-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Assessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patients. A comprehensive cardiovascular evaluation should be conducted before treatment, including a detailed medical history, physical examination, and baseline cardiac imaging. Risk stratification tools can aid in determining the individual patient's risk profile. Close monitoring of cardiac function, including regular assessment of left ventricular ejection fraction (LVEF) and monitoring for signs and symptoms of cardiac dysfunction, is crucial during treatment. Prompt action should be taken if an adverse cardiovascular event is detected, including considering discontinuing or modifying the treatment regimen. Appropriate follow-up care is essential to monitor for long-term cardiac effects and optimize cardiovascular health in breast cancer survivors. Regular cardiovascular assessments, lifestyle modifications, and collaboration between healthcare professionals are important in managing cardiotoxicity effectively.
引用
收藏
页码:385 / 397
页数:13
相关论文
共 50 条
[31]   Heart and cancer: cardio-oncology [J].
Michel, Lars ;
Rassaf, Tienush .
HERZ, 2024, 49 (02) :111-117
[32]   Cardio-oncology: the Nuclear Option [J].
Alvarez, Jorge A. ;
Russell, Raymond R. .
CURRENT CARDIOLOGY REPORTS, 2017, 19 (04)
[33]   Cardio-Oncology: Role of Echocardiography [J].
Villarraga, Hector R. ;
Herrmann, Joerg ;
Nkomo, Vuyisile T. .
PROGRESS IN CARDIOVASCULAR DISEASES, 2014, 57 (01) :10-18
[34]   Understanding Myocardial Metabolism in the Context of Cardio-Oncology [J].
Liu, Jing ;
Chen, Zsu-Zsu ;
Patel, Jagvi ;
Asnani, Aarti .
HEART FAILURE CLINICS, 2022, 18 (03) :415-424
[35]   Cardio-oncology: Implications for Clinical Practice for Women [J].
Seyed Ebrahim Kassaian ;
Bhumika Gandhi ;
Ana Barac .
Current Cardiology Reports, 2022, 24 :1685-1698
[36]   Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer [J].
Crea, Filippo .
EUROPEAN HEART JOURNAL, 2022, 43 (04) :245-248
[37]   Immuno-inflammatory mechanisms in cardio-oncology: new hopes for immunotargeted therapies [J].
Miao, Meiqi ;
Liu, Xinxin ;
Zhang, Han ;
Dai, Hailong .
FRONTIERS IN ONCOLOGY, 2025, 15
[38]   Cardio-oncology: Implications for Clinical Practice for Women [J].
Kassaian, Seyed Ebrahim ;
Gandhi, Bhumika ;
Barac, Ana .
CURRENT CARDIOLOGY REPORTS, 2022, 24 (11) :1685-1698
[39]   Echocardiography and Cardio-Oncology [J].
Negishi, Tomoko ;
Miyazaki, Sakiko ;
Negishi, Kazuaki .
HEART LUNG AND CIRCULATION, 2019, 28 (09) :1331-1338
[40]   The Impact of the Cancer Moonshot on Cardio-Oncology Science [J].
Minasian, Lori M. ;
Adhikari, Bishow B. ;
Dimond, Eileen P. ;
Shelburne, Nonniekaye ;
Shi, Scarlet ;
Desvigne-Nickens, Patrice .
JACC: CARDIOONCOLOGY, 2022, 4 (03) :413-416